



Review

Effect of SGLT2 inhibitors on anemia and their possible clinical implications



Aleix Cases^{a,b}, Secundino Cigarrán^c, José Luis Górriz^{b,d,*}, Julio Nuñez^e

^a Servei de Nefrología, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

^b Grupo de Anemia de la S.E.N., Spain

^c Servicio de Nefrología, Hospital Ríbera-Polusa, Lugo, Spain

^d Servicio de Nefrología, Hospital Clínico Universitario, INCLIVA, Universitat de València, Valencia, Spain

^e Servicio de Cardiología, Hospital Clínico Universitario, INCLIVA, Universitat de València, CIBER Cardiovascular, Spain

ARTICLE INFO

Article history:

Received 1 August 2023

Accepted 11 November 2023

Keywords:

SGLT2 inhibitors

Anemia

Diabetes

Heart failure

Chronic kidney disease

ABSTRACT

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular and renal benefits in patients with type 2 diabetes mellitus, heart failure, or chronic kidney disease. Since the first studies with these drugs, an initial increase in hemoglobin/hematocrit levels was observed, which was attributed to an increase in hemoconcentration associated with its diuretic effect, although it was early apparent that these drugs increased erythropoietin levels and erythropoiesis, and improved iron metabolism. Mediation studies found that the increase in hemoglobin was strongly associated with the cardiorenal benefits of these drugs. In this review, we discuss the mechanisms for improving erythropoiesis and the implication of the increase in hemoglobin on the cardiorenal prognostic benefit of these drugs.

© 2024 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Efecto de los inhibidores del cotransportador sodio-glucosatipo 2 sobre la anemia: posibles implicaciones clínicas

RESUMEN

Los inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT2) han demostrado su beneficio cardiovascular y renal en pacientes con diabetes mellitus tipo 2, insuficiencia cardíaca o enfermedad renal crónica. Desde los primeros estudios con estos fármacos se objetivó un incremento inicial de los niveles de hemoglobina/hematocrito que se atribuyó a un aumento de la hemoconcentración asociados a su efecto diurético, aunque pronto se constató que estos fármacos aumentaban los niveles de eritropoyetina y la eritropoyesis y mejoraban

Palabras clave:

Inhibidores de SGLT2

Anemia

Diabetes

Insuficiencia cardíaca

Enfermedad renal crónica

DOI of original article:

<https://doi.org/10.1016/j.nefro.2023.11.001>.

* Corresponding author.

E-mail address: jlgorriz@gmail.com (J. Luis Górriz).

2013-2514/© 2024 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

el metabolismo férreo. Los estudios de mediación objetivaron que el aumento de hemoglobina se asociaba estrechamente con los beneficios cardiorrenales de estos fármacos. En esta revisión se discuten los mecanismos de mejora de la eritropoyesis y la implicación del aumento de hemoglobina sobre el beneficio pronóstico cardiorrenal de estos fármacos.

© 2024 Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Sodium-glucose cotransporter type 2 (SGLT2i) inhibitors were initially introduced for the treatment of type 2 diabetes mellitus. Cardiovascular safety studies in type 2 diabetic patients demonstrated that these drugs decreased the risk of cardiovascular events (especially congestive heart failure [HF])¹⁻⁵ and also reduce the progression of chronic kidney disease (CKD), as well as the reduction and regression of albuminuria or even preventing its development.⁶⁻¹⁰

Subsequently, studies were performed to demonstrate their benefit in patients with HF, both diabetics and non-diabetics. These additional studies showed that the use of SGLT2-i reduced the number of HF hospitalizations and also decrease the cardiovascular mortality in this population, both with reduced and with preserved ejection fraction¹¹⁻¹⁵ regardless of whether or not they were diabetics or CKD patients.¹⁶

In both diabetic and non-diabetic CKD patients, iSGLT2 has also been shown to reduce CKD progression and albuminuria.¹⁷⁻²⁰ Furthermore, in this setting iSGLT2 decrease the risk of HF hospitalization and cardiovascular mortality,^{5,20} as well as the risk of acute renal failure.²⁰

Effect of sodium-glucose cotransporter type 2 inhibitors on erythropoiesis

Erythropoietin

Since the first clinical trials in patients with type 2 diabetes mellitus, it was observed that SGLT2-i treatment produced an early and sustained increase in hemoglobin/hematocrit levels,²¹⁻²⁴ a fact that has subsequently been confirmed in clinical trials in patients with HF²⁵⁻²⁸ and CKD.²⁹⁻³¹

Hemoglobin/hematocrit changes during iSGLT2 treatment were initially attributed to hemoconcentration due to its diuretic effect and the decrease in plasma volume,²⁸ although it was soon suggested that other mechanisms might be involved, given that its increase exceeded what would be expected by the initial plasma volume contraction and its poor temporal relationship with volume contraction.^{22,29}

In this regard, an initial increase in erythropoietin (EPO) levels and/or reticulocyte counts was observed with the use of these agents, both in patients with either normal^{24,28,32-38} or reduced renal function,²⁹ confirming their direct positive effect on erythropoiesis. Recently, in a post hoc analysis of the Dapagliflozin on Renal Outcomes and cardiovascular Mortality in Patients With Chronic Kidney Disease (DAPA-CKD) study,

it was found that the increase in hematocrit was gradual and reached a maximum about four months after the initiation of the treatment with dapagliflozin, which rules out its relationship with the initial decrease in blood volume.³¹ The increase in erythropoiesis with these drugs could be due to the reversal of relative tissue hypoxia in the proximal tubule as a result of the decreased activity in Na^+/K^+ ATPase pump, secondary to the decrease in sodium reabsorption by inhibition of sodium-glucose cotransporter type 2 (SGLT2). In diabetes mellitus SGLT2 expression is increased. Some studies have shown that repeated damage or hypoxia at the level of the renal proximal tubule may lead to dedifferentiation of EPO-producing cells and their conversion into myofibroblasts, which lose their ability to produce this hormone. Thus, the normalization of renal cortical oxygenation at this level would reduce metabolic stress and improve tubulointerstitial function, restoring the capacity of EPO production by peritubular fibroblasts, stimulating erythropoiesis.³⁹ In addition, inhibition of glucose and sodium reabsorption by SGLT2i in the posterior segments of the nephron favors its distal recovery (e.g., SGLT1). This favors hypoxia at the renal medullary level, stimulating EPO production by interstitial fibroblasts at this location.³⁹ Similarly, CKD due to nephroangiosclerosis is characterized by increased sympathetic nervous activity and activation of the renin-angiotensin-aldosterone system (RAAS), which increases sodium reabsorption in the proximal tubule and thus oxygen consumption; it also decreases sodium influx to the distal nephron, activating tubulo-glomerular feedback.

Another possible effect could be the stimulation of vasopressin synthesis by SGLT2i,⁴⁰ as this hormone has been shown to increase red blood cell count and stimulate erythropoiesis by an EPO-independent mechanism in experimental studies.⁴¹

Finally, the anti-inflammatory effects of SGLT2-i could enhance erythropoiesis by increasing EPO production and the response to EPO by bone marrow erythroblasts.⁴²

Iron metabolism

There are many effects of SGLT2-i on iron metabolism.

Several studies have observed a decrease in hepcidin levels, which could favor intestinal absorption of iron and its mobilization from deposits, thus increasing its availability for erythropoiesis.^{28,34,35} Similarly, there are studies showing a significant reduction in ferritin levels.^{29,33-35,43,44} Erythrocferrone, produced by erythroid precursor cells, acts in the liver decreasing hepcidin expression. In two studies the use of SGLT2i was associated to an increase in erythrocferrone

levels,³⁴ although in one of these studies it did not reach statistical significance.²⁸

Likewise, some studies have shown that treatment with SGLT2-i^{35,44} is accompanied by an increase in transferrin levels or total iron binding capacity^{34,35,43}, soluble transferrin receptor, as well as a decrease in the transferrin saturation index,^{34,35,43} although not in all studies.^{29,33} Similarly, an increase in the expression of transferrin receptor types 1 and 2 has been observed in mononuclear cells.³⁴

All these changes are compatible with an improvement in functional iron deficiency and an increase in intracellular iron availability/utilization, which would favor erythropoiesis and myocardial metabolic efficiency.⁴⁵ In this regard, a recent analysis of a clinical trial in patients with HF and reduced ejection fraction showed that treatment with dapagliflozin was associated with decreased ferritin and increased soluble transferrin receptor. The magnitude of these changes was linked to the degree of the increase in short-term maximal functional capacity.⁴⁴

Mediators of cardiorenal benefits of sodium-glucose type 2 cotransporter inhibitors in pivotal clinical trials

In diabetic patients, anemia appears earlier in the course of renal disease and is more severe than in patients without diabetes.⁴⁶ The presence of anemia is associated with a worse prognosis in diabetics⁴⁷, HF^{26,27,48} and CKD patients.^{31,49–51} Likewise, anemia has been shown to be a factor in progression to end-stage CKD.^{31,50,51}

The aforementioned studies found that treatment with SGLT2-i reduced the prevalence of anemia and the risk of its subsequent development in diabetic patients,^{22–24} with HF^{26,27} or with CKD.^{29–31}

Interestingly, the mediation analyses performed in the different studies of cardiovascular or renal safety of SGLT2-i consistently indicate that the main mediators of cardiovascular^{52–55} and renal^{55,56} benefits of SGLT2-i are increases in hemoglobin/hematocrit, as well as decreases in uric acid, or urine albumin-creatinine ratio. Although being a potential mediator does not imply causality, it is noteworthy that most studies agree on the markers of cardiovascular and renal protection during treatment with these drugs. In patients with HF, the increase in hemoglobin with SGLT2-i⁹ precedes, predicts and is closely associated with reduced risk of events^{53–55} and correction of anemia with SGLT2i is associated with a better prognosis than in those in whom the anemia²⁷ persists. In the DAPA-CKD study, the benefit on renal events with dapagliflozin was greater in anemic subjects than in non-anemic subjects.³¹ In terms of functional parameters, the increase in hemoglobin during treatment with SGLT2i has also been associated with improved oxygen consumption, improved quality of life and decreased natriuretic peptides in patients with HF.⁵⁷

However, it is unlikely that the cardiovascular and renal benefits of SGLT2-i can be attributed to the increase in hemoglobin/hematocrit, since previous studies with erythropoiesis-stimulating agents have not demonstrated a benefit of hemoglobin normalization on cardiovascular

events, including HF, or renal events in patients with CKD,⁵⁸ however an increase in adverse effects have been described. In the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) study, treatment with darbepoetin did not reduce the risk of death or hospitalization for HF, and it was associated with an increase in thrombotic events,⁵⁹ which is contrary to what has been observed with SGLT2-i.

More recently, the use of hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHI) for the treatment of renal anemia have also failed to demonstrate a benefit on cardiovascular or renal events in CKD patients whether they were on dialysis or not, with respect to erythropoiesis-stimulating agents, despite improving ferrokinetics and achieving the same hemoglobin levels with circulating EPO levels within a more physiological range.⁶⁰ All this suggests that the clinical benefits observed in patients on SGLT2-i treatment and their relationship with increased hemoglobin and hematocrit are due to multiple and complex pathophysiological mechanisms, well beyond the direct benefit of increased hemoglobin. Although it cannot be totally ruled out that the improvement in hemoglobin, and the consequent increase in tissue oxygen delivery, has a cardiovascular and renal benefit, which is attenuated by the confusing influence of the adverse cardiovascular effects of treatment with erythropoiesis-stimulating agents or HIF-PHI.

Very recently, an intervention study on the Canagliozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) study has observed that the benefit of increased hematological parameters is greater in patients with lower albuminuria, while in those with albuminuria > 300 mg/g it would be associated to a reduction of albuminuria, although there is a complementary effect between the two.⁶¹

Potential mechanisms explaining the association between changes in hemoglobin/hematocrit and cardiorenal benefits of sodium-glucose cotransporter type 2 inhibitors

In the very short term, hemoconcentration, secondary to its predominantly aquaretic effect, could be the mechanism that largely explains the initial increase in hemoglobin and hematocrit. In this line, a recent study performed in patients with HF and reduced ejection fraction showed an inverse relationship between the increase in hemoglobin and the initial decrease in glomerular filtration rate observed in these patients (another well-known parameter of hemoconcentration in patients treated with vigorous diuretic strategies).⁶² This relationship disappeared after three months, suggesting that there are other mechanisms involved in the increase of hemoglobin in the medium and long term, as previously discussed.⁶²

Similarly, SGLT2-i would increase hemoglobin levels mainly by stimulating endogenous EPO production and enhancing iron kinetics through the stimulation of the hypoxia-inducible factor (HIF) pathway, partly sharing common mechanisms with HIF-PHI. However, SGLT2-i and HIF-PHI differ in some aspects.




Fig. 1 – Beneficial effects of SGLT2i beyond the increase in erythropoiesis. Indirect effects on kidney and heart.^{74,75} (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).
Heart failure, diabetes mellitus and chronic kidney disease favor inflammation, which increases hepcidin levels. This favors functional iron deficiency, decreasing iron availability in the bone marrow and at the myocardial level. Likewise, inflammation reduces erythropoiesis by inhibiting erythropoietin synthesis and its effects on erythropoiesis.
SGLT2i reduce inflammation, functional iron deficiency and increase erythropoietin levels, improving erythropoiesis. In addition, they optimize autophagy, mitochondrial function and decrease apoptosis, oxidative stress and fibrosis, resulting in nephro- and cardioprotection of these drugs.
SGLT2i: sodium-glucose cotransporter type 2 inhibitors; ERFE: erythroferrone; TRf1: transferrin receptor type 1.
Red arrows: deleterious effects. Blue arrows: positive effects.

HIF-PHI inhibitors act by inhibiting several PHIs (including PHD1, PHD2 and PHD3), thereby inhibiting the degradation of both HIF-1 and HIF-2.⁶³ Of these, HIF-2 is the main physiological stimulus for EPO production and also controls the expression of genes involved in iron uptake and tissue distribution (such as bone marrow).⁶⁴ Activation of HIF-1 would not be necessary and could be somewhat counterproductive, given that prolonged activation of this transcription factor favors proinflammatory pathways and accelerates the progression of cardiac and renal injury or angiogenesis.⁶⁵

SGLT2-i decrease HIF-1 levels^{34,66} and by contrast they increase HIF-2 which reduces cellular stress and inflammation and has cytoprotective effects at the cardiac and renal levels.⁶⁵ SGLT2-i increase sirtuin-1,⁶⁷ that directly and selectively activate HIF-2. SGLT2i have been shown to increase HIF-2 at the cardiac level, potentially contributing to their antifibrotic actions.⁶⁸

Another effect suggested in recent studies would be the benefit on EPO production and erythropoiesis by an improvement of tubulointerstitial function.⁶⁹

More recently, proteomic studies shed light on potential mechanisms involved in the cardiorenal protection of SGLT2-i, among which would be the increase in EPO levels, but also has beneficial effects on proteins involved in cardiac contraction/relaxation, iron metabolism, metabolic effects or cardiorenal protection mechanisms, such as the promotion of autophagy or the reduction of oxidative stress, inflammation or fibrosis.⁷⁰⁻⁷²

In this regard, in an analysis of the Myocardial-IRON study, myocardial iron repletion after IV iron carboxymaltose admin-

istration was superior in the subgroup of patients receiving SGLT2i,⁷³ suggesting that they may also improve myocardial iron metabolism, supporting the results from previous studies.⁴⁴

The beneficial effects of SGLT2-i, beyond increasing erythropoiesis are shown in schematic form in Fig. 1.^{74,75}

In conclusion, treatment with SGLT2-i is associated with an increase in hemoglobin levels in the order of 0.5–0.7 g/dL, or its equivalent in hematocrit, probably due to multifactorial mechanisms; among these, improvement in erythropoiesis and in systemic iron metabolism. This increase in hemoglobin is associated in mediation studies with a better cardiorenal prognosis, suggesting that the increase in the hemoglobin and hematocrit could act as parameters monitoring response to treatment.

At the recent ASN (American Society of Nephrology) 2023 congress, the mediation analyses of the DAPA-CKD study were presented, confirming that the benefit on the primary renal event was mainly explained by the increase in hematocrit (35.5%) and the reduction in albuminuria (35.4%); the beneficial effect of the increase in hematocrit was observed in both diabetic and non-diabetic patients.⁷⁶

Likewise, in a recent retrospective study in heart failure patients with reduced ejection fraction and iron deficiency, the increase in hemoglobin levels after IV iron administration was higher in patients treated with SGLT2-i than in those without treatment.⁷⁷ It has been suggested that increased hemoglobin may increase blood viscosity and increase the risk of cardiovascular events.⁷⁸ Alternatively, iron deficiency increases the number and activity of platelets. Similarly, transferrin has

been shown to be involved in thrombosis,^{79,80} so studies are needed on the efficacy and safety of IV iron administration in patients with heart failure and iron deficiency treated with SGLT2-i.

Conflict of interest

The authors declare that they have no conflicts of interest.

REFERENCES

- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med.* 2015;373:2117–28, <http://dx.doi.org/10.1056/NEJMoa1504720>.
- Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med.* 2017;377:644–57, <http://dx.doi.org/10.1056/NEJMoa1611925>.
- Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 2019;380:347–57, <http://dx.doi.org/10.1056/NEJMoa1812389>.
- Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. *N Engl J Med.* 2020;383:1425–35, <http://dx.doi.org/10.1056/NEJMoa2004967>.
- Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. SCORED Investigators. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. *N Engl J Med.* 2021;384:129–39, <http://dx.doi.org/10.1056/NEJMoa2030186>.
- Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med.* 2016;375:323–34, <http://dx.doi.org/10.1056/NEJMoa1515920>.
- Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. *Lancet Diabetes Endocrinol.* 2018;6:691–704, [http://dx.doi.org/10.1016/S2213-8587\(18\)30141-4](http://dx.doi.org/10.1016/S2213-8587(18)30141-4).
- Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. *Lancet Diabetes Endocrinol.* 2019;7:606–17, [http://dx.doi.org/10.1016/S2213-8587\(19\)30180-9](http://dx.doi.org/10.1016/S2213-8587(19)30180-9).
- Cherney DZ, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, et al. VERTIS CV Investigators. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. *Diabetologia.* 2021;64:1256–67, <http://dx.doi.org/10.1007/s00125-021-05407-5>.
- Waijer SW, Xie D, Inzucchi SE, Zinman B, Koitka-Weber A, Mattheus M, et al. Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: a post hoc analysis of the EMPA-REG OUTCOME trial. *J Am Heart Assoc.* 2020;9:e016976, <http://dx.doi.org/10.1161/JAHA.120.016976>.
- Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med.* 2020;383:1413–24, <http://dx.doi.org/10.1056/NEJMoa2022190>.
- McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med.* 2019;381:1995–2008, <http://dx.doi.org/10.1056/NEJMoa1911303>.
- Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med.* 2021;385:1451–61, <http://dx.doi.org/10.1056/NEJMoa2107038>.
- Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med.* 2022;387:1089–98, <http://dx.doi.org/10.1056/NEJMoa2206286>.
- Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. SOLOIST-WHF trial investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. *N Engl J Med.* 2021;384:117–28, <http://dx.doi.org/10.1056/NEJMoa2030183>.
- Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. *Lancet.* 2022;400:757–67, [http://dx.doi.org/10.1016/S0140-6736\(22\)01429-5](http://dx.doi.org/10.1016/S0140-6736(22)01429-5).
- Perkovic V, Jardine MJ, Neal B, Bompain S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med.* 2019;380:2295–306, <http://dx.doi.org/10.1056/NEJMoa1811744>.
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med.* 2020;383:1436–46, <http://dx.doi.org/10.1056/NEJMoa2024816>.
- Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. *N Engl J Med.* 2022;388:117–27, <http://dx.doi.org/10.1056/NEJMoa2204233>.
- Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. *Lancet.* 2022;400:1788–801, [http://dx.doi.org/10.1016/S0140-6736\(22\)02074-8](http://dx.doi.org/10.1016/S0140-6736(22)02074-8).
- Kambay M, Tapoi L, Ureche C, Tanriover C, Cevik E, Demiray A, et al. Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis. *Int Urol Nephrol.* 2022;54:827–41, <http://dx.doi.org/10.1007/s11255-021-02943-2>.
- Stefánsson BV, Heerspink HJL, Wheeler DC, Sjöström CD, Greasley PJ, Sartipy P, et al. Correction of anemia by dapagliflozin in patients with type 2 diabetes. *J Diabetes Complications.* 2020;34:107729, <http://dx.doi.org/10.1016/j.jdiacomp.2020.107729>.
- Kolkailah AA, Wiviott SD, Raz I, Murphy SA, Mosenzon O, Bhatt DL, et al. Effect of dapagliflozin on hematocrit in patients with type 2 diabetes at high cardiovascular risk: observations from DECLARE-TIMI 58. *Diabetes Care.* 2022;45:e27–9, <http://dx.doi.org/10.2337/dc21-1668>.

24. Aberle J, Menzen M, Schmid SM, Terkamp C, Jaeckel E, Rohwedder K, et al. Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes. *Sci Rep.* 2020;10:22396, <http://dx.doi.org/10.1038/s41598-020-78734-z>.
25. Jensen J, Omar M, Kistorp C, Poulsen MK, Tuxen C, Gustafsson I, et al. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial. *Am Heart J.* 2020;228:47-56, <http://dx.doi.org/10.1016/j.ahj.2020.07.011>.
26. Ferreira JP, Anker SD, Butler J, Filippatos G, Iwata T, Salsali A, et al. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced. *Eur J Heart Fail.* 2022;24:708-15, <http://dx.doi.org/10.1002/ejhf.2409>.
27. Docherty KF, Curtain JP, Anand IS, Bengtsson O, Inzucchi SE, Køber L, et al. DAPA-HF Investigators and Committees. Effect of dapagliflozin on anaemia in DAPA-HF. *Eur J Heart Fail.* 2021;23:617-28, <http://dx.doi.org/10.1002/ejhf.2132>.
28. Fuchs Andersen C, Omar M, Glenthøj A, El Fassi D, Møller HJ, Lindholm Kurtzhals JA, et al. Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial. *Eur J Heart Fail.* 2023;5:226-34, <http://dx.doi.org/10.1002/ejhf.2735>.
29. Maruyama T, Takashima H, Oguma H, Nakamura Y, Ohno M, Utsunomiya K, et al. Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease. *Diabetes Technol Ther.* 2019;21:713-20, <http://dx.doi.org/10.1089/dia.2019.0212>.
30. Oshima M, Neuen BL, Jardine MJ, Bakris G, Edwards R, Levin A, et al. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. *Lancet Diabetes Endocrinol.* 2020;8:903-14, [http://dx.doi.org/10.1016/S2213-8587\(20\)30300-4](http://dx.doi.org/10.1016/S2213-8587(20)30300-4).
31. Koshino A, Schechter M, Chertow GM, Vart P, Jongs N, Toto RD, et al. Dapagliflozin and anemia in patients with chronic kidney disease. *NEJM Evid.* 2023;2, <http://dx.doi.org/10.1056/EVIDoa2300049>.
32. Lambers HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. *Diabetes Obes Metab.* 2013;15:853-62, <http://dx.doi.org/10.1111/dom.12127>.
33. Mazer CD, Hare GMT, Connelly PW, Gilbert RE, Shehata N, Quan A, et al. Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. *Circulation.* 2020;141:704-7, <http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044235>.
34. Ghanim H, Abuaysheh S, Hejna J, Green K, Batra M, Makdissi A, et al. Dapagliflozin suppresses hepcidin and increases erythropoiesis. *J Clin Endocrinol Metab.* 2020;105:dgaa057, <http://dx.doi.org/10.1210/clinem/dgaa057>.
35. Docherty KF, Welsh P, Verma S, De Boer RA, O'Meara E, Bengtsson O, et al. DAPA-HF Investigators and Committees. Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. *Circulation.* 2022;146:980-94, <http://dx.doi.org/10.1161/CIRCULATIONAHA.122.060511>.
36. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Barsotti E, Clerico A, et al. Renal Handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. *Diabetes Care.* 2017;40:771-6, <http://dx.doi.org/10.2337/dc16-2724>.
37. Yamada T, Sakaguchi K, Okada Y, Miura H, Otowa-Suematsu N, So A, et al. Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation. *Diabetol Int.* 2020;12:197-206, <http://dx.doi.org/10.1007/s13340-020-00474-2>.
38. Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. *Circulation.* 2020;142:1028-39, <http://dx.doi.org/10.1161/CIRCULATIONAHA.120.045691>.
39. Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. *Circulation.* 2019;139:1985-7, <http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038881>.
40. Eickhoff MK, Dekkers CCJ, Kramers BJ, Laverman GD, Frimodt-Møller M, Jørgensen NR, et al. Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors. *J Clin Med.* 2019;8:779, <http://dx.doi.org/10.3390/jcm8060779>.
41. Mayer B, Németh K, Krepuska M, Myneni VD, Maric D, Tisdale JF, et al. Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia. *Sci Transl Med.* 2017;9:eaao1632, <http://dx.doi.org/10.1126/scitranslmed.aao1632>.
42. Koshino A, Schechter M, Sen T, Vart P, Neuen BL, Neal B, et al. Interleukin-6 and cardiovascular and kidney outcomes in patients with type 2 diabetes: new insights from CANVAS. *Diabetes Care.* 2022;45:2644-52, <http://dx.doi.org/10.2337/dc22-0866>.
43. Thiele K, Rau M, Hartmann NK, Möllmann J, Jankowski J, Böhm M, et al. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: data from a randomized, placebo-controlled study. *Diabetes Obes Metab.* 2021;23:2814-8, <http://dx.doi.org/10.1111/dom.14517>.
44. Lorenzo M, Jacobs-Cachá C, Palau P, Amiguet M, Seller J, Núñez E, et al. on behalf of DAPA-VO2 investigators. Short-term changes in peakVO₂ after initiation of dapagliflozin in heart failure across iron status. *JACC Heart Failure.* 2023;11:1611-22.
45. Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. *Circulation.* 2022;146:1383-405, <http://dx.doi.org/10.1161/CIRCULATIONAHA.122.061732>.
46. Deray G, Heurtier A, Grimaldi A, Launay Vacher V, Isnard Bagnis C. Anemia and diabetes. *Am J Nephrol.* 2004;24:522-6, <http://dx.doi.org/10.1159/000081058>.
47. Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. *J Am Soc Nephrol.* 2005;16:3403-10, <http://dx.doi.org/10.1681/ASN.2005030226>.
48. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. *J Am Coll Cardiol.* 2008;52:818-27, <http://dx.doi.org/10.1016/j.jacc.2008.04.061>.
49. Portolés J, Gorri J, Rubio E, de Alvaro F, García F, Alvarez-Chivas V, et al. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. *BMC Nephrol.* 2013;14:2, <http://dx.doi.org/10.1186/1471-2369-14-2>.
50. Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O. The impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes — a systematic literature

- review. *Int J Nephrol.* 2020;2020:7692376, <http://dx.doi.org/10.1155/2020/7692376>.
51. Wittbrodt ET, James G, Kumar S, van Haalen H, Chen H, Sloand JA, et al. Contemporary outcomes of anemia in US patients with chronic kidney disease. *Clin Kidney J.* 2021;15:244–52, <http://dx.doi.org/10.1093/ckj/sfab195>.
 52. Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. *Diabetes Care.* 2018;41:356–63, <http://dx.doi.org/10.2337/dc17-1096>.
 53. Fitchett D, Inzucchi SE, Zinman B, Wanner C, Schumacher M, Schmoor C, et al. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. *ESC Heart Fail.* 2021;8:4517–27, <http://dx.doi.org/10.1002/ehf2.13615>.
 54. Li J, Woodward M, Perkovic V, Figtree GA, Heerspink HJL, Mahaffey KW, et al. Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes. *JACC Heart Fail.* 2020;8:57–66, <http://dx.doi.org/10.1016/j.jchf.2019.08.004>.
 55. Segar MW, Kolkailah AA, Frederick R, Pong A, Cannon CP, Cosentino F, et al. Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus. *Diabetes Obes Metab.* 2022;24:1829–39, <http://dx.doi.org/10.1111/dom.14769>.
 56. Li J, Neal B, Perkovic V, de Zeeuw D, Neuen BL, Arnott C, et al. Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. *Kidney Int.* 2020;98:769–77, <http://dx.doi.org/10.1016/j.kint.2020.04.051>.
 57. Lorenzo M, Miñana G, Palau P, Amiguet M, Seller J, García Pinilla JM, et al. DAPA-VO2 Investigators. Short-term changes in hemoglobin and changes in functional status, quality of life and natriuretic peptides after initiation of dapagliflozin in heart failure with reduced ejection fraction. *J Card Fail.* 2023;29:849–54, <http://dx.doi.org/10.1016/j.cardfail.2023.02.008>.
 58. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. *Ann Intern Med.* 2010;153:23–33, <http://dx.doi.org/10.7326/0003-4819-153-1-201007060-00252>.
 59. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al. RED-HF Committees; RED-HF Investigators. Treatment of anemia with darbepoetin alfa in systolic heart failure. *N Engl J Med.* 2013;368:1210–9, <http://dx.doi.org/10.1056/NEJMoa1214865>.
 60. Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M, et al. for Conference Participants. Novel anemia therapies in chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. *Kidney Int.* 2023;104:655–80, <http://dx.doi.org/10.1016/j.kint.2023.05.009>.
 61. Doi Y, Hamano T, Yamaguchi S, Sakaguchi Y, Kaimori JY, Isaka Y. Mediators between canagliflozin and renoprotection vary depending on patient characteristics: insights from the CREDENCE trial. *Diabetes Obes Metab.* 2023;25:2944–53, <http://dx.doi.org/10.1111/dom.15191>.
 62. Miñana G, de la Espriella R, Palau P, Amiguet M, Seller J, García Pinilla JM, et al. en representación de los investigadores del DAPA-VO2. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction. *Rev Esp Cardiol (Engl Ed).* 2023;76:783–92, <http://dx.doi.org/10.1016/j.rec.2023.03.007>.
 63. Sanghani NS, Haase VH. Hypoxia-inducible Factor activators in renal anemia: current clinical experience. *Adv Chronic Kidney Dis.* 2019;26:253–66, <http://dx.doi.org/10.1053/j.ackd.2019.04.004>.
 64. Samanta D, Prabhakar NR, Semenza GL. Systems biology of oxygen homeostasis. *Wiley Interdiscip Rev Syst Biol Med.* 2017;9:e1382, <http://dx.doi.org/10.1002/wsbm.1382>.
 65. Packer M. Mechanistic and clinical comparison of the erythropoietic effects of SGLT2 inhibitors and prolyl hydroxylase inhibitors in patients with chronic kidney disease and renal anemia. *Am J Nephrol.* 2024;55(2):255–9, <http://dx.doi.org/10.1159/000531084>.
 66. Bessho R, Takiyama Y, Takiyama T, Kitsunai H, Takeda Y, Sakagami H, et al. Hypoxia-inducible factor-1 α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. *Sci Rep.* 2019;9:14754, <http://dx.doi.org/10.1038/s41598-019-51343-1>.
 67. Packer M. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. *Nat Rev Cardiol.* 2023;20:443–62, <http://dx.doi.org/10.1038/s41569-022-00824-4>.
 68. Yang Z, Li T, Xian J, Chen J, Huang Y, Zhang Q, Lin X, Lu H, Lin Y. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2 α signaling pathway in arrhythmogenic cardiomyopathy. *FASEB J.* 2022;36:e22410, <http://dx.doi.org/10.1096/fj.202200243R>.
 69. Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. *J Clin Med Res.* 2016;8:844–7, <http://dx.doi.org/10.14740/jocmr2760w>.
 70. Ferrannini E, Murthy AC, Lee YH, Muscilli E, Weiss S, Ostroff RM, et al. Mechanisms of sodium-glucose cotransporter 2 inhibition: insights from large-scale proteomics. *Diabetes Care.* 2020;43:2183–9, <http://dx.doi.org/10.2337/dc20-0456>.
 71. Zhao YX, Borjigin S, Yan ZL. Functional annotation and enrichment analysis of differentially expressed serum proteins in patients with type 2 diabetes after dapagliflozin. *World J Diabetes.* 2022;13:224–39, <http://dx.doi.org/10.4239/wjd.v13.i3.224>.
 72. Zannad F, Ferreira JP, Butler J, Filippatos G, Januzzi JL, Sumin M, et al. Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights from the EMPEROR Program. *Eur Heart J.* 2022;43:4991–5002, <http://dx.doi.org/10.1093/eurheartj/ehac495>.
 73. Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, Vargas-Delgado AP, Mancini D, Sartori S, et al. Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study. *JACC Heart Fail.* 2021;9:578–89, <http://dx.doi.org/10.1016/j.jchf.2021.04.014>.
 74. Packer M. Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes. *Diabetes Obes Metab.* 2023;25:1143–6, <http://dx.doi.org/10.1111/dom.14963>.
 75. Packer M. How can sodium-glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron-deficient? Implications for understanding iron homeostasis in heart failure. *Eur J Heart Fail.* 2022;24:2287–96, <http://dx.doi.org/10.1002/ejhf.2731>.
 76. Schechter M, Jongs N, Chertow G, McMurray J, Correa-Rotter R, et al. Mediators of the kidney protective effects of dapagliflozin in patients with CKD with or without type 2 diabetes. *Congreso ASN.* 2023. TH-PO 1058.
 77. Marques P, Matias P, Packer M, Vieira JT, Vasques-Nóvoa F, Sharma A, et al. Erythropoietic response after

- intravenousiron in patients with heart failure and reduced ejection fraction with and without background treatment withsodium-glucose cotransporter 2 inhibitors. Eur J Heart Fail. 2023;25(12):2191–8, <http://dx.doi.org/10.1002/ejhf.2992>.
78. Imprialos KP, Boutari C, Stavropoulos K, Doumas M, Karagiannis AI. Stroke paradox with SGLT-2 inhibitors: a playof chance or a viscosity-mediated reality? J Neurol Neurosurg Psychiatry. 2017;88:249–53, <http://dx.doi.org/10.1136/jnnp-2016-314704>.
79. Evstatiiev R, Bukaty A, Jimenez K, Kulnigg-Dabsch S, Surman L, Schmid W, et al. Iron deficiency alters megakaryopoiesisand platelet phenotype independent of thrombopoietin. Am J Hematol. 2014;89:524–9, <http://dx.doi.org/10.1002/ajh.23682>.
80. Tang X, Zhang Z, Fang M, Han Y, Wang G, Wang S, et al. Transferrin plays a central role in coagulation balance byinteracting with clotting factors. Cell Res. 2020;30:119–32, <http://dx.doi.org/10.1038/s41422-019-0260-6>.